A phase II study of atezolizumab with rituximab, gemcitabine and oxaliplatin in patients with relapsed or refractory diffuse large b-cell lymphoma who are not candidates for high-dose therapy
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine; Oxaliplatin; Rituximab; Rituximab
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- Acronyms ARGO
- 31 Aug 2018 Biomarkers information updated
- 18 May 2018 Status changed from not yet recruiting to recruiting.
- 30 Apr 2018 Planned End Date changed from 30 Jun 2023 to 1 Jun 2023.